OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland. Show more

115 Pullman Crossing Road, Grasonville, MD, 21638, United States

Biotechnology

Healthcare

Market Cap

69.78M

52 Wk Range

$1.15 - $2.57

Previous Close

$1.70

Open

$1.71

Volume

299,976

Day Range

$1.66 - $1.72

Enterprise Value

89.0M

Cash

269.8K

Avg Qtr Burn

-3.73M

Insider Ownership

23.45%

Institutional Own.

5.73%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OST-HER2 Details Pediatric lung metastatic osteosarcoma	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OST-504 Details 2L prostate cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.